Home > Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.

Roelsgaard, Ida K and Esbensen, Bente A and Ostergaard, Mikkel and Rollefstad, Silvia and Semb, Anne G and Christensen, Robin and Thomsen, Thordis [The Cochrane Library] . (2019) Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. Wiley. Cochrane Database of Systematic Reviews (9) Art. no.: CD012958. DOI: 10.1002/14651858.CD012958.pub2

URL: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...


Background: Chronic inflammatory joint diseases (IJDs) affect 1% to 2% of the population in developed countries. IJDs include rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other forms of spondyloarthritis (SpA). Tobacco smoking is considered a significant environmental risk factor for developing IJDs. There are indications that smoking exacerbates the symptoms and worsens disease outcomes.

 

Objectives: The objective of this review was to investigate the evidence for effects of smoking cessation interventions on smoking cessation and disease activity in smokers with IJD.

 

Main results: We included two studies with 57 smokers with a diagnosis of rheumatoid arthritis (RA). We identified no studies including other IJDs. One pilot study compared a smoking cessation intervention specifically for people with RA with a less intensive, generic smoking cessation intervention. People included in the study had a mean age of 56.5 years and a disease duration of 7.7 years (mean).

 

The second study tested effects of an eight‐week cognitive‐behavioural patient education intervention on cardiovascular disease (CVD) risk for people with RA and compared this with information on CVD risk only. The intervention encouraged participants to address multiple behaviours impacting CVD risk, including smoking cessation, but did not target smoking cessation alone. People included in the study had a mean age of 62.2 years (intervention group) and 60.8 years (control group), and disease duration of 11.6 years (intervention group) and 14.1 years (control group). It was not appropriate to perform a meta‐analysis of abstinence data from the two studies due to clinical heterogeneity between interventions. Neither of the studies individually provided evidence to show benefit of the interventions tested. Only one study reported on adverse effects. These effects were non‐serious, and numbers were comparable between trial arms. Neither of the studies assessed or reported disease activity or any of the predefined secondary outcomes. We assessed the overall certainty of evidence as very low due to indirectness, imprecision, and high risk of detection bias based on GRADE.

 

Authors' conclusions: We found very little research investigating the efficacy of smoking cessation intervention specifically in people with IJD. Included studies are limited by imprecision, risk of bias, and indirectness. Neither of the included studies investigated whether smoking cessation intervention reduced disease activity among people with IJD. High‐quality, adequately powered studies are warranted. In particular, researchers should ensure that they measure disease markers and quality of life, in addition to long‐term smoking cessation.

Item Type:Evidence resource
Publication Type:Protocol
Drug Type:Tobacco
Intervention Type:AOD disorder
Source:The Cochrane Library
Date:September 2019
Publisher:Wiley
Number:9
EndNote:View
Subjects:B Substances > Tobacco (cigarette smoking)
G Health and disease > State of health > Physical health
HJ Treatment method > Substance disorder treatment method > Cessation of substance use

Repository Staff Only: item control page